DPP4 and type 2 diabetes mellitus: In this nationwide cohort of patients with type 2 diabetes receiving insulin therapy, the addition of GLP-1 RAs was associated with significantly lower risks of cardiovascular events, major microvascular complications, and all-cause mortality compared with the addition of DPP-4 inhibitors or sulfonylureas.